AstraZeneca's IL-33 antibody shows promise for COPD

AstraZeneca's R&D chief cites internal progress on an IL-33 antibody targeting COPD inflammation

AstraZeneca's R&D chief recently highlighted internal progress with an IL-33 antibody designed to reduce COPD-related inflammation. The work shows potential to lower hospitalizations for millions of Americans affected by chronic obstructive pulmonary disease. This approach targets a specific inflammatory pathway linked to COPD progression, which could ease the burden of frequent hospital visits and emergency care. However, this remains an early-stage research finding within AstraZeneca's internal pipeline. The exact scale of potential hospitalization reduction remains unquantified, and no clinical trials have yet advanced this therapy to patient use. For now, the benefit is theoretical but could eventually lower healthcare costs for a population where COPD drives significant hospitalization rates. The source provides only this limited update on internal R&D activity, with no details on trial stages or future pathways.

Source: Fierce Biotech